Do analysts rate CRIS or DOMH?

Curis presently has a consensus price target of $17.00, indicating a potential upside of 4,804.79%. Given Curis' stronger consensus rating and higher possible upside, research analysts plainly believe Curis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, CRIS or DOMH?

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 1.43 -$7.58M -$1.19 N/A Dominari $123.10M 0.54 -$22.43M -$4.03 N/A

Is CRIS or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Dominari -31.37% -206.20% -155.26%

Does the media prefer CRIS or DOMH?

In the previous week, Curis had 6 more articles in the media than Dominari. MarketBeat recorded 7 mentions for Curis and 1 mentions for Dominari. Curis' average media sentiment score of 0.29 beat Dominari's score of 0.00 indicating that Curis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dominari 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CRIS or SGMO more profitable?

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Is BOLT or CRIS more profitable?

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics -455.15% -100.89% -48.23% Curis -80.29% N/A -181.57%

Which has stronger earnings and valuation, CRIS or AMGN?

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 1.43 -$7.58M -$1.19 N/A Amgen $36.75B 5.49 $7.71B $14.37 26.04

Is CRIS or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Curis' net margin of -80.29%. Amgen's return on equity of 137.41% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Amgen 20.96% 137.41% 13.28%

Does the media prefer CRIS or AMGN?

In the previous week, Amgen had 26 more articles in the media than Curis. MarketBeat recorded 33 mentions for Amgen and 7 mentions for Curis. Amgen's average media sentiment score of 1.01 beat Curis' score of 0.29 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amgen 26 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Is CRIS or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to Curis' net margin of -80.29%. Gilead Sciences' return on equity of 48.19% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Gilead Sciences 30.99% 48.19% 18.28%

Does the media favor CRIS or GILD?

In the previous week, Gilead Sciences had 16 more articles in the media than Curis. MarketBeat recorded 23 mentions for Gilead Sciences and 7 mentions for Curis. Gilead Sciences' average media sentiment score of 1.41 beat Curis' score of 0.29 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gilead Sciences 20 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Curis (CRIS) Competitors

$0.35 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.36 +0.01 (+3.58%)

As of 07/2/2026 07:49 PM Eastern

Compare

CRIS vs. DOMH, SGMO, BOLT, AMGN, and GILD

Should you buy Curis stock or one of its competitors? MarketBeat compares Curis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curis include Dominari (DOMH), Sangamo Therapeutics (SGMO), Bolt Biotherapeutics (BOLT), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry.

How does Curis compare to Dominari?

Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Curis presently has a consensus price target of $17.00, indicating a potential upside of 4,804.79%. Given Curis' stronger consensus rating and higher possible upside, research analysts plainly believe Curis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Curis had 6 more articles in the media than Dominari. MarketBeat recorded 7 mentions for Curis and 1 mentions for Dominari. Curis' average media sentiment score of 0.29 beat Dominari's score of 0.00 indicating that Curis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dominari	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.43	-$7.58M	-$1.19	N/A
Dominari	$123.10M	0.54	-$22.43M	-$4.03	N/A

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Dominari	-31.37%	-206.20%	-155.26%

Curis has a beta of 3.08, suggesting that its share price is 208% more volatile than the broader market. Comparatively, Dominari has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

30.0% of Curis shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 5.8% of Curis shares are owned by insiders. Comparatively, 55.3% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Curis beats Dominari on 11 of the 16 factors compared between the two stocks.

How does Curis compare to Sangamo Therapeutics?

Curis (NASDAQ:CRIS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Curis has higher earnings, but lower revenue than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.43	-$7.58M	-$1.19	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

30.0% of Curis shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Curis currently has a consensus target price of $17.00, indicating a potential upside of 4,804.79%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Curis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Curis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, Curis had 7 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 7 mentions for Curis and 0 mentions for Sangamo Therapeutics. Curis' average media sentiment score of 0.29 beat Sangamo Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the media.

Company	Overall Sentiment
Curis	Neutral
Sangamo Therapeutics	Neutral

Summary

Curis beats Sangamo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Curis compare to Bolt Biotherapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	1.01	-$33.38M	-$16.33	N/A
Curis	$9.44M	1.43	-$7.58M	-$1.19	N/A

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 5.8% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bolt Biotherapeutics currently has a consensus price target of $34.67, suggesting a potential upside of 755.97%. Curis has a consensus price target of $17.00, suggesting a potential upside of 4,804.79%. Given Curis' higher possible upside, analysts clearly believe Curis is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Curis had 7 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 7 mentions for Curis and 0 mentions for Bolt Biotherapeutics. Curis' average media sentiment score of 0.29 beat Bolt Biotherapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Curis	Neutral

Bolt Biotherapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Curis has a beta of 3.08, meaning that its share price is 208% more volatile than the broader market.

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Curis	-80.29%	N/A	-181.57%

Summary

Curis beats Bolt Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Curis compare to Amgen?

Curis (NASDAQ:CRIS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Amgen has a net margin of 20.96% compared to Curis' net margin of -80.29%. Amgen's return on equity of 137.41% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Amgen	20.96%	137.41%	13.28%

30.0% of Curis shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amgen has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.43	-$7.58M	-$1.19	N/A
Amgen	$36.75B	5.49	$7.71B	$14.37	26.04

Curis currently has a consensus target price of $17.00, suggesting a potential upside of 4,804.79%. Amgen has a consensus target price of $355.50, suggesting a potential downside of 4.98%. Given Curis' higher probable upside, analysts clearly believe Curis is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

In the previous week, Amgen had 26 more articles in the media than Curis. MarketBeat recorded 33 mentions for Amgen and 7 mentions for Curis. Amgen's average media sentiment score of 1.01 beat Curis' score of 0.29 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amgen	26 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Curis has a beta of 3.08, meaning that its share price is 208% more volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

Summary

Amgen beats Curis on 14 of the 17 factors compared between the two stocks.

How does Curis compare to Gilead Sciences?

Curis (NASDAQ:CRIS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Curis has a beta of 3.08, suggesting that its share price is 208% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Curis. Curis is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.43	-$7.58M	-$1.19	N/A
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.88

Gilead Sciences has a net margin of 30.99% compared to Curis' net margin of -80.29%. Gilead Sciences' return on equity of 48.19% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Gilead Sciences	30.99%	48.19%	18.28%

30.0% of Curis shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.8% of Curis shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Curis currently has a consensus price target of $17.00, indicating a potential upside of 4,804.79%. Gilead Sciences has a consensus price target of $158.41, indicating a potential upside of 20.67%. Given Curis' higher probable upside, equities analysts plainly believe Curis is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Gilead Sciences had 16 more articles in the media than Curis. MarketBeat recorded 23 mentions for Gilead Sciences and 7 mentions for Curis. Gilead Sciences' average media sentiment score of 1.41 beat Curis' score of 0.29 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Curis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gilead Sciences	20 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gilead Sciences beats Curis on 13 of the 16 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRIS vs. The Competition

Export

Metric	Curis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.51M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-0.29	21.61	28.02	24.70
Price / Sales	1.43	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.83	8.66	10.96	6.46
Net Income	-$7.58M	$23.81M	$3.57B	$337.01M
7 Day Performance	14.01%	3.39%	2.12%	1.69%
1 Month Performance	-26.77%	10.81%	5.25%	3.81%
1 Year Performance	-81.16%	62.61%	33.29%	23.90%

Curis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRIS Curis	3.7445 of 5 stars	$0.35 flat	$17.00 +4,804.8%	-81.2%	$13.51M	$9.44M	N/A	60	News Coverage Gap Up
DOMH Dominari	0.2902 of 5 stars	$3.12 -0.5%	N/A	-44.2%	$70.43M	$123.10M	N/A	4
SGMO Sangamo Therapeutics	1.2375 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
BOLT Bolt Biotherapeutics	2.3748 of 5 stars	$4.02 +3.1%	$34.67 +761.9%	-33.6%	$7.72M	$7.70M	N/A	90	Short Interest Increase
AMGN Amgen	3.918 of 5 stars	$361.26 +0.2%	$354.42 -1.9%	+25.4%	$194.94B	$36.75B	25.14	31,500	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRIS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curis (CRIS) Competitors

CRIS vs. DOMH, SGMO, BOLT, AMGN, and GILD

How does Curis compare to Dominari?

Summary

How does Curis compare to Sangamo Therapeutics?

Summary

How does Curis compare to Bolt Biotherapeutics?

Summary

How does Curis compare to Amgen?

Summary

How does Curis compare to Gilead Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curis (CRIS) Competitors

CRIS vs. DOMH, SGMO, BOLT, AMGN, and GILD

How does Curis compare to Dominari?

Do analysts rate CRIS or DOMH?

Does the media prefer CRIS or DOMH?

Which has higher valuation and earnings, CRIS or DOMH?

Is CRIS or DOMH more profitable?

Which has more volatility and risk, CRIS or DOMH?

Do insiders & institutionals have more ownership in CRIS or DOMH?

Summary

How does Curis compare to Sangamo Therapeutics?

Which has preferable earnings & valuation, CRIS or SGMO?

Is CRIS or SGMO more profitable?

Do institutionals and insiders have more ownership in CRIS or SGMO?

Do analysts rate CRIS or SGMO?

Which has more volatility & risk, CRIS or SGMO?

Does the media prefer CRIS or SGMO?

Summary

How does Curis compare to Bolt Biotherapeutics?

Which has higher earnings and valuation, BOLT or CRIS?

Do insiders and institutionals hold more shares of BOLT or CRIS?

Do analysts recommend BOLT or CRIS?

Does the media refer more to BOLT or CRIS?

Which has more risk and volatility, BOLT or CRIS?

Is BOLT or CRIS more profitable?

Summary

How does Curis compare to Amgen?

Is CRIS or AMGN more profitable?

Do insiders & institutionals hold more shares of CRIS or AMGN?

Which has stronger earnings and valuation, CRIS or AMGN?

Do analysts prefer CRIS or AMGN?

Does the media prefer CRIS or AMGN?

Which has more volatility & risk, CRIS or AMGN?

Summary

How does Curis compare to Gilead Sciences?

Which has more risk & volatility, CRIS or GILD?

Which has higher valuation & earnings, CRIS or GILD?

Is CRIS or GILD more profitable?

Do institutionals and insiders hold more shares of CRIS or GILD?

Do analysts recommend CRIS or GILD?

Does the media favor CRIS or GILD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools